Trial reportClinical journal of the American Society of Nephrology : CJASN2008
Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy.
Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis.International urology and nephrology · 2021Pooled it
- Pooled it
- Rituximab therapy for membranous nephropathy: a systematic review.Clinical journal of the American Society of Nephrology : CJASN · 2009Pooled it
- Fractional excretion of IgG in idiopathic membranous nephropathy with nephrotic syndrome: a predictive marker of risk and drug responsiveness.BMC nephrology · 2014Trial
- Rituximab in idiopathic membranous nephropathy.Journal of the American Society of Nephrology : JASN · 2012Trial
- Prospective Cohort Study of Obinutuzumab in Rituximab-Resistant Primary Membranous Nephropathy.Kidney international reports · 2026Article
- Efficacy and safety of ripertamab for treating primary membranous nephropathy among adults: a multicenter, retrospective, real-world study.Frontiers in immunology · 2025Observational
- The monitoring of B lymphocytes in non-lymphoma patients following rituximab treatment.Frontiers in immunology · 2024Article
- Sexual dimorphic response to rituximab treatment: A longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome.Frontiers in pharmacology · 2022Article
- Rituximab in Membranous Nephropathy.Kidney international reports · 2021Review
- A Comprehensive Phenotypic and Functional Immune Analysis Unravels Circulating Anti-Phospholipase A2 Receptor Antibody Secreting Cells in Membranous Nephropathy Patients.Kidney international reports · 2020Article
- Treatment of membranous nephropathy: time for a paradigm shift.Nature reviews. Nephrology · 2017Review
- Review
- Treatment with rituximab in idiopathic membranous nephropathy.Clinical kidney journal · 2016Article
- Functional Human Podocytes Generated in Organoids from Amniotic Fluid Stem Cells.Journal of the American Society of Nephrology : JASN · 2016Article
- Angiotensin II contributes to diabetic renal dysfunction in rodents and humans via Notch1/Snail pathway.The American journal of pathology · 2013Article
- Depletion of B lymphocytes in idiopathic membranous glomerulopathy: results from patients with extended follow-up.Nephron extra · 2013Article
- B cell depletion: rituximab in glomerular disease and transplantation.Nephron extra · 2013Review
- Treatment of idiopathic membranous nephropathy.Journal of the American Society of Nephrology : JASN · 2012Review
- Triggers, bullets and targets, puzzle of membranous nephropathy.Nephro-urology monthly · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesIn idiopathic membranous nephropathy (IMN), CD(20) B-cell depletion by rituximab may induce nephrotic syndrome (NS) remission. Whether this is associated with kidney function restoration and regression of the glomerular pathology was evaluated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Treatment-induced morphofunctional changes were evaluated in 7 IMN patients consenting to repeat functional and morphologic evaluations after stable disease remission achieved by four weekly rituximab (375 mg/m(2)) infusions.
resultsOver a median of 21 mo from rituximab administration, NS remission was associated with 8.5-fold increase versus baseline in sodium fractional clearance from 1.56 to 13.25, decrease in renal plasma flow from 440.8 to 276.6 ml/min per 1.73 m(2), stable glomerular filtration rate, and increased renal vascular resistances. Changes in sodium fractional clearance and hemoglobin concentration were positively correlated (r = 0.82). Biopsy reevaluations showed complete or partial reabsorption of subepithelial deposits. Median (interquartile range) IgG4 staining score decreased from 3 (3-3) to 1 (0-2), whereas total numbers of slit diaphragms (0.27; range, 0.19 to 0.30 versus 0.86; range, 0.53 to 1.16 slits/mum glomerular basement membrane) and percentages of those with electron-dense diaphragm (55.2; range, 42.0 to 62.0 versus 78.5; range, 73.0 to 82.7 of all slits) significantly increased in parallel with amelioration of glomerular ultrastructural changes. Changes in slit frequency and albumin fractional clearance were negatively correlated (r = -0.79).
conclusionsIn human IMN, treatment-induced NS remission is associated with restoration of sodium homeostasis and kidney hemodynamics, and regression of the glomerular changes underlying proteinuria. These effects are likely to translate into long-term renoprotection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.